PharmaCyte Biotech (PMCB) discloses director share grant and options

Rhea-AI Filing Summary

PharmaCyte Biotech director Jonathan Schechter reported recent equity compensation activity. On 12/12/2025, he acquired 150,000 shares of common stock, with 67,500 shares withheld to cover taxes related to vesting restricted stock units, so the withholding did not involve an open-market sale.

On 04/25/2025, he was also granted stock options covering 63,233 shares of common stock at an exercise price of $1.22 per share, expiring on 04/24/2035. These options are scheduled to vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider SCHECHTER JONATHAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--
Tax Withholding	Common Stock	67,500	$1.02	$69K
Grant/Award	Stock Option (Right to Buy)	63,233	$0.00	--

Holdings After Transaction: Common Stock — 200,000 shares (Direct); Stock Option (Right to Buy) — 63,233 shares (Direct)

Footnotes (1)

1. Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHECHTER JONATHAN

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NV 89169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
04/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		150,000	A	$0	200,000	D
Common Stock	12/12/2025		F		67,500(1)	D	$1.02	132,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.22	04/25/2025		A		63,233		(2)	04/24/2035	Common Stock	63,233	$0	63,233	D

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.

2. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter. This transaction is late due to an inadvertent administrative error and not any error of Mr. Schechter.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Jonathan Schechter	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PharmaCyte Biotech (PMCB) report for Jonathan Schechter?

The report shows that director Jonathan Schechter acquired 150,000 shares of PharmaCyte Biotech common stock on 12/12/2025, had 67,500 shares withheld to cover taxes on vesting restricted stock units, and received stock options on 63,233 shares.

Were any of Jonathan Schechter’s PMCB transactions open-market sales?

No. The 67,500 shares noted with transaction code F represent shares withheld by PharmaCyte Biotech to satisfy tax liabilities on restricted stock unit vesting and are explicitly described as not an open-market sale or other market transaction.

What are the terms of the stock options granted to Jonathan Schechter by PMCB?

Jonathan Schechter received a stock option on 04/25/2025 to purchase 63,233 shares of PharmaCyte Biotech common stock at an exercise price of $1.22 per share. The option expires on 04/24/2035 and is scheduled to vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.

What role does Jonathan Schechter have at PharmaCyte Biotech (PMCB)?

The report identifies Jonathan Schechter as a director of PharmaCyte Biotech, Inc., and the form is filed as a single reporting person filing.

Why were 67,500 PMCB shares associated with Jonathan Schechter marked with code F?

Transaction code F corresponds to shares used to pay taxes. The 67,500 shares are described as withheld by PharmaCyte Biotech to satisfy Schechter’s tax liability upon vesting of restricted stock units, rather than being sold in the market.